Unicycive Therapeutics Faces Securities Class Action Lawsuit
Shareholders have initiated a class action lawsuit against Unicycive Therapeutics, alleging that the company misled investors regarding manufacturing capabilities.
Unicycive Therapeutics is the subject of a securities class action lawsuit naming the company’s CEO and CFO as defendants. The litigation centers on claims that the executives failed to provide accurate disclosures concerning the status and performance of a third-party contract manufacturer.
The complaint alleges that the company issued misleading information to shareholders about the severity of issues within its supply chain. Investors claim that these omissions concealed material facts that, when eventually brought to light, resulted in significant financial losses.
Legal firm Levi & Korsinsky is representing the class and has designated November 2, 2026, as the deadline for investors to petition the court to serve as lead plaintiff. The litigation highlights the risks associated with reliance on external manufacturing partners in the biotechnology sector.